This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated Q2 Sep 2026 vs Q2 Sep 2025: revenue up 79.7 percent; profit after tax up 1,259 percent
BODALCHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Unaudited consolidated quarter ended 30 September 2026: revenue was Rs 8,633.74 million versus Rs 4,804.52 million in September 2025; profit after tax was Rs 814.44 million versus Rs 59.93 million. Operating margin before interest, depreciation and tax rose to 12.4 percent from 4.8 percent. Consolidated half-year: revenue of Rs 15,724.15 million; profit after tax of Rs 1,118.23 million. Turkish figures were restated for hyperinflation.
Revenue, profit and margin gains are positive for shareholders, but half-year operating cash flow fell to Rs 282.73 million and needs monitoring.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹863.4 Cr | ₹480.5 Cr | +79.7% |
| Operating profit | ₹69.41 Cr | −₹14.34 Cr | turned positive |
| Profit after tax | ₹81.44 Cr | ₹5.99 Cr | +1,259.0% |
| EBITDA margin | 12.4% | 4.8% | +7.6 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.